Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) $ in Millions		12 Months Ended
		Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Segment Reporting Information [Line Items]
Reportable segments | Segment		4
Revenues		$ 44,915	$ 39,211	$ 32,218
Subtotal reportable segments		8,393	10,028	7,794
Restructuring and other costs		(114)	(197)	(99)
Amortization of acquisition-related intangible assets		(2,395)	(1,761)	(1,667)
Consolidated operating income		8,393	10,028	7,794
Interest income		272	43	65
Interest expense		(726)	(536)	(553)
Other income/(expense)		(104)	(694)	(76)
Income before income taxes		7,835	8,841	7,230
Depreciation of property, plant and equipment		986	831	658
Total assets		97,154	95,123	69,052
Capital expenditures		2,243	2,523	1,474
Life Sciences Solutions
Segment Reporting Information [Line Items]
Restructuring and other costs		(30)	(129)	(34)
Total assets		21,848	22,751	20,209
Capital expenditures		490	810	392
Analytical Instruments
Segment Reporting Information [Line Items]
Restructuring and other costs		(1)	(6)	(26)
Total assets		10,019	9,692	9,773
Capital expenditures		140	79	74
Specialty Diagnostics
Segment Reporting Information [Line Items]
Restructuring and other costs		(68)	(18)	(9)
Total assets		5,542	6,010	6,534
Capital expenditures		112	167	175
Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Restructuring and other costs		(12)	(35)	(23)
Total assets		51,281	52,639	22,711
Capital expenditures		1,403	1,327	772
Corporate/other
Segment Reporting Information [Line Items]
Total assets	[1]	8,464	4,031	9,825
Capital expenditures		98	140	61
Total Reportable Segments
Segment Reporting Information [Line Items]
Subtotal reportable segments		10,985	12,138	9,556
Consolidated operating income		10,985	12,138	9,556
Total Reportable Segments | Life Sciences Solutions
Segment Reporting Information [Line Items]
Revenues		13,532	15,631	12,168
Subtotal reportable segments		5,582	7,817	6,109
Consolidated operating income		5,582	7,817	6,109
Depreciation of property, plant and equipment		214	197	140
Total Reportable Segments | Analytical Instruments
Segment Reporting Information [Line Items]
Revenues		6,624	6,069	5,124
Subtotal reportable segments		1,507	1,197	808
Consolidated operating income		1,507	1,197	808
Depreciation of property, plant and equipment		83	83	76
Total Reportable Segments | Specialty Diagnostics
Segment Reporting Information [Line Items]
Revenues		4,763	5,659	5,343
Subtotal reportable segments		1,024	1,280	1,368
Consolidated operating income		1,024	1,280	1,368
Depreciation of property, plant and equipment		75	128	100
Total Reportable Segments | Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Revenues		22,511	14,862	12,245
Subtotal reportable segments		2,872	1,844	1,271
Consolidated operating income		2,872	1,844	1,271
Depreciation of property, plant and equipment		614	423	342
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues		(2,515)	(3,010)	(2,662)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Cost of revenues adjustments		(46)	(8)	(6)
Selling, general and administrative expenses adjustments		(37)	(144)	10
Restructuring and other costs		(114)	(197)	(99)
Amortization of acquisition-related intangible assets		$ (2,395)	$ (1,761)	$ (1,667)

[1] Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.